A new class of prolylcarboxypeptidase inhibitors, part 1: discovery and evaluation
Thomas H Graham1, Wensheng Liu, Andreas Verras
1Department of Medicinal Chemistry, Merck Research Laboratories, Rahway, NJ 07065-0900, USA. thomas.graham@merck.com
Abstract:
A new structural class of potent prolylcarboxypeptidase (PrCP) inhibitors was discovered by high-throughput screening. The series possesses a tractable SAR profile with sub-nanomolar in vitro IC(50) values. Compared to prior inhibitors, the new series demonstrated minimal activity shifts in pure plasma and complete ex vivo plasma target engagement in mouse plasma at the 20 h post-dose time point (po). In addition, the in vivo level of CNS and non-CNS drug exposure was measured.
More Related Videos
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Protein-protein Interfaces
Drug Discovery: Overview
Treatment for Pulmonary Arterial Hypertension: Prostacyclin Receptor Agonists
These agonists bind to the IPR receptor situated on the plasma membrane of the pulmonary artery smooth muscle cells. This binding triggers a cascade of reactions known as the GS-AC-cAMP-PKA pathway. This pathway results in the relaxation of smooth muscle...
Prodrugs
Prodrugs help overcome...
Inhibitors of Bacterial Protein Synthesis


